Surging Type 1 Diabetes Prevalence Highlights Need For Effective Insulin Therapy Is Supporting Development Across The Short-Acting Insulin Market

The Business Research Company’s 2026 market reports feature advanced enhancements such as market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights, delivering more actionable and strategically valuable research.

What Market Value Trend Is Expected For The Short-Acting Insulin Market From 2026 To 2030?

The short-acting insulin market has shown strong growth in recent years. It is projected to increase from $11.54 billion in 2025 to $12.14 billion in 2026, demonstrating a compound annual growth rate (CAGR) of 5.3%. The historical expansion of this market can be attributed to factors such as the high prevalence of diabetes, widespread adoption of insulin therapy, hospital-based diabetes management, the expansion of insulin access programs, and improved diabetes diagnosis rates.

The short-acting insulin market is projected to experience robust expansion over the coming years. Its valuation will reach $14.87 billion in 2030 at a compound annual growth rate (CAGR) of 5.2%. This anticipated increase can be attributed to several factors such as the growing prevalence of type 2 diabetes, greater reliance on insulin, the rise of home-based diabetes management, advancements in insulin delivery methods, and an escalating need for fast-acting insulin. Key developments expected during this period involve an increasing call for post-meal blood glucose regulation, wider application of rapid-acting insulin analogues, more widespread adoption of pre-filled insulin pens, the expansion of intensive insulin therapy protocols, and a heightened emphasis on precise glycemic control.

Download A Free Sample Report For Comprehensive Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=21287&type=smp

What Market Drivers Are Helping Shape The Short-Acting Insulin Market Expansion?

The expansion of the short-acting insulin market is expected to be fueled by the growing occurrence of type 1 diabetes. Type 1 diabetes, an autoimmune condition, involves the body’s destruction of insulin-producing cells, making lifelong insulin therapy essential. The rising frequency of Type 1 diabetes is attributed to genetic factors, environmental triggers, and an increase in autoimmune disorders. Short-acting insulin plays a vital role in managing type 1 diabetes by ensuring swift blood sugar regulation and mimicking the natural insulin process. For instance, in December 2023, according to Diabetes Australia, an Australia-based organization focused on diabetes awareness, around 134,000 Australians were living with Type 1 diabetes in 2022, with this figure climbing to 135,423 in 2023. Therefore, the increasing prevalence of type 1 diabetes is a key driver for the growth of the short-acting insulin market.

Which Segment Divisions Form The Structure Of The Short-Acting Insulin Market?

The short-acting insulin market covered in this report is segmented –

1) By Formulation: Regular Insulin, Rapid-Acting Insulin

2) By Dosage Form: Vials, Pre-filled Pens, Cartridges

3) By Route Of Administration: Subcutaneous, Intravenous

4) By Patient Type: Type 1 Diabetes, Type 2 Diabetes

5) By Distribution Channel: Pharmacies, Hospital Pharmacies, Online Pharmacies

Subsegments:

1) By Regular Insulin: Human Regular Insulin, Animal-Derived Regular Insulin, Other Regular Insulin

2) By Rapid-Acting Insulin: Insulin Lispro, Insulin Aspart, Insulin Glulisine

What Trends Are Affecting The Short-Acting Insulin Market Dynamics?

Leading companies in the short-acting insulin market are concentrating on advanced products, like interchangeable rapid-acting insulin biologics, to improve glycemic regulation and offer versatile substitution choices for diabetic patients. An interchangeable rapid-acting insulin biologic refers to a biologically derived insulin variant that quickly lowers blood glucose levels after eating and has received regulatory authorization to be exchanged for another equivalent insulin product without requiring a new prescription, thus providing adaptability in diabetes management and ensuring consistent glycemic control. For instance, in July 2025, Biocon Biologics, a US-based biosimilars firm based in India and the U.S., secured FDA approval for Kirsty (insulin aspart xjhz), marking it as the first and only interchangeable rapid-acting insulin aspart in the United States. Kirsty is a biosimilar to NovoLog (insulin aspart), supported by clinical and analytical data that shows no meaningful distinctions in safety, efficacy, purity, or potency. It is provided as a 100 units/mL formulation, available in both a single-patient-use prefilled pen (for subcutaneous use) and a multi-dose vial (for both subcutaneous and intravenous administration), with the goal of enhancing glycemic control in adults and children afflicted with diabetes mellitus.

Which Companies Form The Competitive Landscape Of The Short-Acting Insulin Market?

Major companies operating in the short-acting insulin market are Sanofi S.A., Eli Lilly and Company, Novo Nordisk A/S, Biocon Limited, Lupin Limited, Wockhardt Ltd., Julphar (Gulf Pharmaceutical Industries), Geropharm LLC, Bioton S.A., Gan & Lee Pharmaceuticals Co. Ltd., Lannett Company Inc., MannKind Corporation, ADOCIA S.A.S., Baxter International Inc., Tonghua Dongbao Pharmaceutical Co. Ltd., United Laboratories International Holdings Ltd., Bharat Biotech International Ltd., Shanghai Fosun Pharmaceutical Group Co. Ltd., Dongbao Enterprise Group Co. Ltd., Aspen Pharmacare Holdings Limited

Access The Complete Short-Acting Insulin Market Report:

https://www.thebusinessresearchcompany.com/report/short-acting-insulin-global-market-report

Which Region Stands As The Largest Contributor To The Short-Acting Insulin Market?

North America was the largest region in the short-acting insulin market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the short-acting insulin market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Access Short-Acting Insulin Market Report for Deeper Competitive Insights

https://www.thebusinessresearchcompany.com/sample.aspx?id=21287&type=smp

Browse Through More Reports Similar to the Global Short-Acting Insulin Market 2026, By The Business Research Company

Insuman Market Report 2026

https://www.thebusinessresearchcompany.com/report/insuman-global-market-report

Instant Tea Premix Market Report 2026

https://www.thebusinessresearchcompany.com/report/instant-tea-premix-global-market-report

Technical Insulation Market Report 2026

https://www.thebusinessresearchcompany.com/report/technical-insulation-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas: +1 310-496-7795